Insider Selling: LeMaitre Vascular Inc (NASDAQ:LMAT) CEO Sells 332 Shares of Stock
LeMaitre Vascular Inc (NASDAQ:LMAT) CEO George W. Lemaitre sold 332 shares of LeMaitre Vascular stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $34.67, for a total transaction of $11,510.44. Following the completion of the transaction, the chief executive officer now owns 3,135,398 shares of the company’s stock, valued at approximately $108,704,248.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
NASDAQ:LMAT traded up $0.65 during mid-day trading on Friday, hitting $35.53. 81,445 shares of the stock traded hands, compared to its average volume of 121,261. The business’s 50-day moving average price is $31.97 and its 200 day moving average price is $29.47. The company has a market cap of $662.49 million, a PE ratio of 42.30, a price-to-earnings-growth ratio of 3.88 and a beta of 1.23. LeMaitre Vascular Inc has a 12-month low of $21.79 and a 12-month high of $38.99.
LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Wednesday, July 24th. The medical instruments supplier reported $0.23 EPS for the quarter, beating the consensus estimate of $0.21 by $0.02. The company had revenue of $29.48 million during the quarter, compared to analysts’ expectations of $28.90 million. LeMaitre Vascular had a net margin of 16.72% and a return on equity of 13.15%. LeMaitre Vascular’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.43 earnings per share. As a group, sell-side analysts predict that LeMaitre Vascular Inc will post 0.86 EPS for the current year.
Several equities analysts have recently weighed in on LMAT shares. First Analysis upgraded shares of LeMaitre Vascular from a “neutral” rating to an “outperform” rating and lifted their target price for the stock from $29.00 to $37.00 in a research note on Thursday, July 25th. ValuEngine upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Wednesday, September 4th. Lake Street Capital lifted their target price on shares of LeMaitre Vascular from $27.00 to $34.00 and gave the stock a “hold” rating in a research note on Thursday, July 25th. Zacks Investment Research upgraded shares of LeMaitre Vascular from a “hold” rating to a “strong-buy” rating and set a $38.00 target price for the company in a research note on Saturday, July 27th. Finally, BidaskClub raised shares of LeMaitre Vascular from a “buy” rating to a “strong-buy” rating in a research note on Friday. Three investment analysts have rated the stock with a hold rating, three have given a buy rating and two have assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $35.33.
A number of large investors have recently modified their holdings of the stock. Royal Bank of Canada grew its stake in LeMaitre Vascular by 14.2% during the second quarter. Royal Bank of Canada now owns 41,016 shares of the medical instruments supplier’s stock valued at $1,148,000 after acquiring an additional 5,111 shares in the last quarter. DF Dent & Co. Inc. grew its stake in LeMaitre Vascular by 32.1% during the second quarter. DF Dent & Co. Inc. now owns 104,794 shares of the medical instruments supplier’s stock valued at $2,932,000 after acquiring an additional 25,454 shares in the last quarter. Amundi Pioneer Asset Management Inc. purchased a new position in LeMaitre Vascular during the second quarter valued at approximately $17,623,000. Nuveen Asset Management LLC purchased a new position in LeMaitre Vascular during the second quarter valued at approximately $2,612,000. Finally, Cubist Systematic Strategies LLC grew its stake in LeMaitre Vascular by 135.5% during the second quarter. Cubist Systematic Strategies LLC now owns 15,957 shares of the medical instruments supplier’s stock valued at $446,000 after acquiring an additional 9,181 shares in the last quarter. 78.53% of the stock is owned by institutional investors.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.